Scholarlink

Objective <p>This study aims to evaluate the impact of diabetic ketoacidosis (DKA) on clinical outcomes among intensive care unit (ICU) patients diagnosed with COVID-19 and concurrent diabetes.</p> Methods <p>A retrospective analysis was conducted on ICU patients diagnosed with both COVID-19 and diabetes at a tertiary-level hospital. Patients were stratified into two groups, non-DKA and DKA, based on the presence of DKA. Comparative analyses were performed to assess clinical characteristics, laboratory parameters, treatment modalities, and prognostic outcomes between the two groups.</p> Results <p>The study included 111 ICU patients with COVID-19 and concurrent diabetes, comprising 88 patients in the non-DKA group and 23 patients in the DKA group. Compared to the non-DKA group, the DKA group exhibited a significantly higher proportion of female patients, younger age, and lower prevalence of hypertension, cardiac, and renal comorbidities (<i>p</i> &lt; 0.05). The overall mortality rate was 43.5% in the DKA group, which did not significantly differ from the 55.7% observed in the non-DKA group (<i>p</i> = 0.336).</p> Conclusion <p>Among patients with COVID-19 and concurrent diabetes, the presence of DKA is not associated with increased mortality. This observation may be attributed to the younger age of patients in the DKA group, reduced organ support requirements, and shorter treatment duration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of the impact of diabetic ketoacidosis on the outcomes of ICU patients with COVID-19 and concurrent diabetes: A single-center retrospective cohort study

  • 期刊论文

  • 发表日期：

    2025年3月6日

查看全文
  • Li Liu,
  • Zengzhu He,
  • Simin Tao,
  • Hongbin Hu,
  • Jiaxin Duan,
  • Yue Ouyang,
  • Leyang Ma,
  • Junying Bao,
  • Tong Sha,
  • Yaoyuan Zhang,
  • Zhenhua Zeng

摘要

Objective

This study aims to evaluate the impact of diabetic ketoacidosis (DKA) on clinical outcomes among intensive care unit (ICU) patients diagnosed with COVID-19 and concurrent diabetes.

Methods

A retrospective analysis was conducted on ICU patients diagnosed with both COVID-19 and diabetes at a tertiary-level hospital. Patients were stratified into two groups, non-DKA and DKA, based on the presence of DKA. Comparative analyses were performed to assess clinical characteristics, laboratory parameters, treatment modalities, and prognostic outcomes between the two groups.

Results

The study included 111 ICU patients with COVID-19 and concurrent diabetes, comprising 88 patients in the non-DKA group and 23 patients in the DKA group. Compared to the non-DKA group, the DKA group exhibited a significantly higher proportion of female patients, younger age, and lower prevalence of hypertension, cardiac, and renal comorbidities (p < 0.05). The overall mortality rate was 43.5% in the DKA group, which did not significantly differ from the 55.7% observed in the non-DKA group (p = 0.336).

Conclusion

Among patients with COVID-19 and concurrent diabetes, the presence of DKA is not associated with increased mortality. This observation may be attributed to the younger age of patients in the DKA group, reduced organ support requirements, and shorter treatment duration.